Early LMWH prophylaxis in surgical patients with severe hypertensive intracerebral hemorrhage

This retrospective cohort study examined the efficacy and safety of early pharmacological prophylaxis for venous thromboembolism using low-molecular-weight heparin calcium in surgical patients with severe hypertensive intracerebral hemorrhage. The cohort comprised 123 patients admitted between September 2021 and February 2025. The intervention involved initiating prophylaxis within a specific timeframe, although the exact timing was not detailed in the available information. No comparator group was reported for this analysis.

The primary outcome measured was the incidence of lower extremity deep vein thrombosis. However, the main results regarding the incidence rates or comparative effectiveness were not reported in the provided evidence. Consequently, no specific numerical data on efficacy or safety outcomes could be extracted to inform clinical decision-making directly from this text.

Safety data, including adverse events, serious adverse events, discontinuations, and tolerability, were not reported in the input. The study design is observational, which inherently limits the ability to establish causal relationships between the intervention and outcomes. Key limitations regarding the study population, follow-up duration, and potential confounding factors were not detailed in the provided information.

The practice relevance of these findings remains uncertain due to the absence of reported main results and safety data. Clinicians should interpret these preliminary observations with caution, recognizing that the evidence is incomplete and does not currently support definitive recommendations for early LMWH use in this specific population without further data.